TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06474442: A Multicenter, Single-blind, Single-dose, Randomized, Phase Ⅱa Trial to Evaluate the Safety, Tolerability and Efficacy of Intrastromal BD111 Gene Editing Therapy in Adults With HSV-1 Stromal Keratitis

Sponsor: Shanghai BDgene Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06474442 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06474442 Rescue Dossier →